|Bid||13.30 x 1100|
|Ask||13.43 x 3000|
|Day's Range||12.72 - 13.99|
|52 Week Range||1.17 - 14.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Endocyte Inc’s (NASDAQ:ECYT) track record on a high level, to giveRead More...
Although the widely-followed NASDAQ Composite Index itself has yet to re-take the high it hit in March, these individual issues continue to show real strength. The higher highs of Apple tend to get the most media attention, but many other NASDAQ stocks were also breaking out of previous price ranges and establishing fresh 52-week highs. This group I've selected includes a toy manufacturer, a hot biotech company, an Texas oil and gas exploration and production firm, a Canadian paper company and a radio broadcaster that broke out to a new 12-year price level.
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
The West Lafayette, Indiana-based company said it had a loss of 16 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
Endocyte Inc’s (NASDAQ:ECYT): Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The US$751.08M market-cap company announced a latestRead More...
Zacks.com highlights: Stoneridge, FGL Holdings, Lindblad Expeditions Holdings, Endocyte and Knoll
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 18 cents. The biopharmaceutical company posted revenue of $12,000 in the period. For the year, the company reported ...
Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.
Categories: Yahoo FinanceGet free summary analysis Endocyte, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Endocyte, Inc. – Madrigal Pharmaceuticals, Inc., Nektar Therapeutics and Verastem, Inc. (MDGL-US, NKTR-US and VSTM-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.03 ... Read more (Read more...)